Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (121-130 of 225) with videos related to

Pageof 23
Sort By:
Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intentRichard M Gewanter, Kenneth E Rosenzweig, Joe Yujiao Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2012
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239Ritsuko Komaki, Rebecca Paulus, David S Ettinger, et al.
The Journal of Liquid Biopsy|April 13, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testingBenjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
The Journal of Liquid Biopsy|June 29, 2026
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461]Benjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)Roger B Cohen, Corey J Langer, George Rajan Simon, et al.
Journal of the American College of Radiology : JACR|January 31, 2009
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intentKenneth E Rosenzweig, Benjamin Movsas, Jeff Bradley, et al.
Clinical Lung Cancer|July 14, 2023
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimensWilliam P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, et al.
Clinical Lung Cancer|November 20, 2016
Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung CancerStephen J Bagley, Steven Vitale, Suhong Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracyJeffrey C Thompson, Wei-Ting Hwang, Christiana Davis, et al.
American Journal of Clinical Oncology|September 28, 2011
ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancerRoy H Decker, Corey J Langer, Kenneth E Rosenzweig, et al.
Pageof 23

Showing results (121-130 of 225) with videos related to

Sort By:
Pageof 23
Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intentRichard M Gewanter, Kenneth E Rosenzweig, Joe Yujiao Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2012
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239Ritsuko Komaki, Rebecca Paulus, David S Ettinger, et al.
The Journal of Liquid Biopsy|April 13, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testingBenjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
The Journal of Liquid Biopsy|June 29, 2026
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461]Benjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)Roger B Cohen, Corey J Langer, George Rajan Simon, et al.
Journal of the American College of Radiology : JACR|January 31, 2009
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intentKenneth E Rosenzweig, Benjamin Movsas, Jeff Bradley, et al.
Clinical Lung Cancer|July 14, 2023
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimensWilliam P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, et al.
Clinical Lung Cancer|November 20, 2016
Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung CancerStephen J Bagley, Steven Vitale, Suhong Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracyJeffrey C Thompson, Wei-Ting Hwang, Christiana Davis, et al.
American Journal of Clinical Oncology|September 28, 2011
ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancerRoy H Decker, Corey J Langer, Kenneth E Rosenzweig, et al.
Pageof 23